Continued Transparency in the U.S.

We commit to continued transparency in the U.S. around our pricing decisions.

Our principles reflect both a desire to help our stakeholders better understand our pricing decisions and to advance a more informed discussion of issues related to the pricing of medicines. To maintain an open dialogue and recognize calls for continued transparency in our pricing actions, we will annually disclose our average aggregate U.S. list and net price changes from the prior calendar year. These data illustrate how the U.S. healthcare system impacts the way pricing changes accrue to manufacturers versus others in the healthcare delivery continuum. The data also also highlight our discrete role in the U.S. healthcare system, i.e., what we as a maker of medicines can control. We believe this information contributes to better-informed discussions to improve patient access and affordability.

While our efforts focus on securing affordable coverage of our medicines for patients, it is important to note that patient cost-sharing and coverage decisions are ultimately made by payors and employers, not manufacturers of the medicines.

While list prices often receive the most public attention, they do not reflect the price patients pay at the pharmacy counter, nor do they typically reflect the price Sanofi is paid for our medicines. List prices are not the prices typically paid by the insurers, employers, or pharmacy benefit managers who purchase our medicines on behalf of patients in their respective health plans. We negotiate discounts and rebates with payors, designed to offer the healthcare system lower prices in exchange for greater access and affordability for patients with insurance. List prices also fail to capture the substantial mandated discounts and rebates, sometimes required by law, provided to government programs, including those provided in Medicare Part D, Medicaid, and the 340B drug pricing programs.

Net prices are what Sanofi receives after discounts, rebates, and fees are paid to health plans and other parts of the healthcare system.  Net prices also take into account copay expenses that help reduce patient prescription medicine costs.

Simply put, patients’ out-of-pocket costs depend on how their healthcare insurance coverage is structured and the extent to which their healthcare insurance coverage passes negotiated discounts to patients.